Exela Pharma Sciences Revenue and Competitors

Lenoir, NC USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Exela Pharma Sciences's estimated annual revenue is currently $69.5M per year.(i)
  • Exela Pharma Sciences's estimated revenue per employee is $201,000

Employee Data

  • Exela Pharma Sciences has 346 Employees.(i)
  • Exela Pharma Sciences grew their employee count by 5% last year.

Exela Pharma Sciences's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.8M294%N/AN/A
#2
$3.2M160%N/AN/A
#3
$83.2M4147%N/AN/A
#4
$31M15456%N/AN/A
#5
$66.6M2650%$35MN/A
#6
$10.9M546%N/AN/A
#7
$6.8M34-6%N/AN/A
#8
$165.7M21614%$250.7MN/A
#9
$26.5M132-11%$637.8KN/A
#10
$49.4M2466%N/AN/A
Add Company

What Is Exela Pharma Sciences?

Exela Pharma Sciences, a fast-growing specialty pharmaceutical company, focuses on developing, manufacturing and marketing generic and proprietary injectable and sterile ophthalmic products that keep the healthcare provider and patient in mind. Our goal is to deliver high quality, affordable products that make a difference in people's lives, and also meet the needs of the healthcare providers that treat them. Exela targets the development and manufacturing of generic and proprietary injectable and sterile ophthalmic products with high barriers to market entry, via an Abbreviated New Drug Approval or 505(b)(2) regulatory pathway. We develop products that enhance the patient or provider experience such as easing the burden of administration, providing an improved safety profile, faster drug perparation, or reduce drug waste. In other words, we strive to improve patient outcomes while reducing overall health care costs.

keywords:N/A

N/A

Total Funding

346

Number of Employees

$69.5M

Revenue (est)

5%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Exela Pharma Sciences News

2022-04-06 - Eton Pharmaceuticals Gets FDA Approval for Cysteine Hydrochloride Injection

... the U.S. Food and Drug Administration for its cysteine hydrochloride injection, a bioequivalent generic of Exela Pharma Sciences' Elcys.

2022-04-06 - Eton Pharmaceuticals Announces FDA Approval of Cysteine ...

Prior to 2019, cysteine was sold in the United States as a “grandfathered” or “unapproved” product. In 2019, Exela Pharma Sciences received FDA...

2022-04-06 - FDA approves Eton Pharmaceuticals' cysteine hydrochloride ...

Eton's drug is a bioequivalent generic of Exela Pharma Sciences' Elcys, which the FDA approved in 2019. The FDA granted Eton 180 days of...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$147.1M4106%N/A
#2
$299.1M11879%N/A